[Brain metastasis: clinical and cognitive assessments]
Carole Ramirez1, Marie Blonski, Catherine Belin
1Hôpital Roger-Salengro, unité de neuro-oncologie, service de neurochirurgie, 2, rue Émile-Laine, CHRU de Lille, 59037 Lille, France. caroleramirez@free.fr
Bulletin Du Cancer
|January 24, 2013
Summary
Brain metastases (BM) are increasingly common. A validated cognitive test battery is recommended for assessing cognitive deficits in BM patients, improving prognosis and quality of life.
Area of Science:
- Neuro-oncology
- Cognitive Neuroscience
Context:
- Brain metastases (BM) incidence is rising due to better treatments, diagnostics, and an aging population.
- Symptoms vary by location and complications, with headaches and cognitive deficits being common.
- Existing assessment tools like Karnofsky Performance Scale and Mini Mental State Examination (MMSE) are often inadequate.
Purpose:
- To highlight the underestimation of cognitive deficits in brain metastases patients.
- To introduce a validated, short cognitive test battery for assessing these deficits.
- To emphasize the importance of cognitive assessment for prognosis and quality of life.
Summary:
- A validated 7-domain cognitive test battery assesses attention, memory, processing speed, and executive functions.
- This battery is relevant, feasible, and shows good patient compliance.
- It is recommended for evaluating cognitive functions in patients with brain metastases.
Impact:
- Improved detection and management of cognitive deficits in brain metastases patients.
- Enhanced understanding of the impact of cognitive function on patient outcomes.
- Provides a standardized, effective tool for clinical assessment and research.
Related Concept Videos
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...